Hyundai Pharmaceutical Co., Ltd. announces an Equity Buyback for KRW 2,000 million worth of its shares.
June 28, 2019 at 06:47 am
Share
Hyundai Pharmaceutical Co., Ltd. (KOSE:A004310) announces a share repurchase program. Under the program, the company will repurchase up to KRW 2,000 worth of its shares pursuant to a contract with Samsung Securities Co. Ltd. The purpose of the program is to improve shareholder value and to stabilize stock price. The program will expire on June 26, 2020. As of June 27, 2019, the company had 4,618,891 shares in treasury within scope available for dividend and had no shares in treasury through other repurchase.
HYUNDAI PHARMACEUTICAL CO.,LTD is a Korea-based company principally engaged in the manufacture and distribution of pharmaceuticals and beverages. The Company mainly provides two categories of products: pharmaceuticals, including ophthalmological tablets, clopidogrel bisulfate, mirtazapine tablets and others, which are applied in the treatment of depressive disorder, hypertension, hemostatics and others, as well as healthcare food products, including vitamin products, calcium supplements and others. It also provides dietary various beverages and medical equipment. The Company mainly distributes its products within domestic market. In addition, the Company also involves in the leasing business.